Cortexyme, Inc. (CRTX) News & Overview - Discounting Cash Flows
CRTX
Cortexyme, Inc.
CRTX (NASDAQ)

CRTX's Business Model

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Sector & Industry Healthcare / Biotechnology
Website https://www.cortexyme.com
CEO (Chief Executive Officer) Casey Lynch
Number of Employees
IPO date May 9, 2019

CRTX Latest News

Contact
CountryUS
Address269 E Grand Ave
CitySouth San Francisco
StateCA
Phone14159105717
Zip Code94080
Other Identifiers
CIK0001662774
ISINUS22053A1079
CUSIP22053A107
Open1.91
Previous Close1.9
Volume272.2 Thou.
Average VolumeNone
Day’s Range1.86 – 1.97
52 Week RangeNone
MA (50)None
MA (200)None
Market Cap70.45 Mil.
Shares Out.36.13 Mil.
Earnings DateAug 08, 2022
Beta
Last Dividend
EPS
PE

Industry Competitors for CRTX

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us